Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

109 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
Navari RM. Navari RM. Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1577-86. doi: 10.1517/17425250903407289. Expert Opin Drug Metab Toxicol. 2009. PMID: 19929251 Review.
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
Rapoport BL, Aapro M, Chasen MR, Jordan K, Navari RM, Schnadig I, Schwartzberg L. Rapoport BL, et al. Drug Des Devel Ther. 2017 Sep 5;11:2621-2629. doi: 10.2147/DDDT.S133943. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28919712 Free PMC article. Review.
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
Chasen M, Urban L, Schnadig I, Rapoport B, Powers D, Arora S, Navari R, Schwartzberg L, Gridelli C. Chasen M, et al. Support Care Cancer. 2017 Jan;25(1):85-92. doi: 10.1007/s00520-016-3388-7. Epub 2016 Aug 24. Support Care Cancer. 2017. PMID: 27557833 Free PMC article. Clinical Trial.
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
Chow R, Chiu L, Navari R, Passik S, Chiu N, Popovic M, Lam H, Pasetka M, Chow E, DeAngelis C. Chow R, et al. Support Care Cancer. 2016 Feb;24(2):1001-1008. doi: 10.1007/s00520-015-3000-6. Epub 2015 Nov 4. Support Care Cancer. 2016. PMID: 26530228 Review.
The current status of the use of palonosetron.
Navari R. Navari R. Expert Opin Pharmacother. 2013 Jul;14(10):1281-4. doi: 10.1517/14656566.2013.799141. Epub 2013 May 7. Expert Opin Pharmacother. 2013. PMID: 23647207
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B, Schwartzberg L, Chasen M, Powers D, Arora S, Navari R, Schnadig I. Rapoport B, et al. Eur J Cancer. 2016 Apr;57:23-30. doi: 10.1016/j.ejca.2015.12.023. Epub 2016 Feb 4. Eur J Cancer. 2016. PMID: 26851398 Clinical Trial.
An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia.
Castellino FJ, Donahue DL, Navari RM, Ploplis VA, Walsh M. Castellino FJ, et al. Blood. 2011 Jan 6;117(1):283-9. doi: 10.1182/blood-2010-07-299057. Epub 2010 Sep 21. Blood. 2011. PMID: 20858853 Free PMC article.
109 results
Jump to page
Feedback